In a nutshell This study evaluated the long-term outcomes of patients with advanced (stage 3 – 4) non-Hodgkin’s lymphoma (NHL) who received radioimmunotherapy before allogeneic stem cell transplantation (alloSCT). This study concluded that this treatment regimen improved survival in most of these patients. Some background AlloSCT involves...
Read MoreIn a nutshell This study looked at the effectiveness of venetoclax-rituximab (Venclexta–Rituxan) in patients with unresponsive or relapsed chronic lymphocytic leukemia (CLL). Researchers found that this treatment improved survival in patients with CLL. Some background Chronic lymphocytic leukemia is a cancer of the bone marrow. This can...
Read MoreIn a nutshell This study reviewed recent recommendations in the management of patients with diffuse large B cell lymphoma (DLBCL). Some background DLBCL is the most common type of non-Hodgkin lymphoma (NHL). The current standard treatment includes chemotherapy and immunotherapy such as R-CHOP (rituximab, cyclophosphamide, doxorubicin,...
Read MoreIn a nutshell This trial is examining the effectiveness of a new drug called uproleselan for patients with acute myeloid leukemia (AML). The main outcome to be measured will be overall survival. This study is being conducted in the United States. The details Acute myeloid leukemia (AML) is a cancer of the bone marrow. It leads to an abnormal immune...
Read MoreIn a nutshell This study wanted to assess the safety and effectiveness of inotuzumab ozogamicin (InO; Besponsa) for the treatment of children with unresponsive acute lymphoblastic leukemia (ALL). Researchers found that InO was safe and effective in this group of patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone...
Read More
In a nutshell This study evaluated the safety and effectiveness of a new targeted therapy (INCB040093) with or without itacitinib in patients with relapsed or refractory (does not respond to treatment) lymphoma. This study concluded that this new agent was well-tolerated and showed promising effectiveness in these patients. Some background...
Read More
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and...
Read More
In a nutshell This study evaluated the long-term outcomes of ibrutinib (Imbruvica) treatment in patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma (MCL). This study concluded that ibrutinib is effective and well-tolerated in these patients. Some background MCL is a rare but aggressive type of non-Hodgkin’s...
Read More
In a nutshell This study evaluated the safety and effectiveness of resminostat in heavily pre-treated patients with relapsed or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that resminostat was effective and well-tolerated in these patients. Some background Histone deacetylase inhibitors (HDIs)...
Read More
In a nutshell This study looked at the safety and effectiveness of bosutinib (Bosulif) in the treatment of chronic myeloid leukemia (CML). Researchers found that bosutinib was effective in patients who have failed other similar drug treatments. Some background Chronic myeloid leukemia (CML) is a cancer of the bone marrow. This can lead to abnormal...
Read More
In a nutshell This article investigated the safety and effectiveness of adding daratumumab (Darzalex) to bortezomib (Velcade) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the addition of daratumumab is safe and gave the greatest benefit to...
Read More
In a nutshell This study looked at the effectiveness of adding inotuzumab ozogamicin (Besponsa) and blinatumomab (Blincyto) to low-intensity chemotherapy in the treatment of ALL. Researchers found that this combination of treatment was effective in these patients. Some background Acute lymphoblastic leukemia (ALL) is a cancer of the bone marrow. This...
Read More
